Prospects for anti-BLyS treatment of systemic lupus erythematosus

Abstract

Review of literature on the analysis of current data on the efficacy of belimumab (BLM) in systemic lupus erythematosus (SLE). It provides data on the high efficacy of BLM in high and medium activity of SLE in patients with joints damage, skin lesions and high immunological activity. The paper describes clinical cases of a rituximab and belimumab combination therapy in SLE patients.